PCP vs Ketamine: Differences, Effects, Medical Use and Addiction Risk

PCP and ketamine are related dissociative drugs that both block NMDA receptors, but they are not interchangeable. PCP has no current routine accepted human medical use in the United States and is encountered primarily as an illicit drug. Ketamine is an FDA-approved Schedule III general anesthetic with legitimate medical use, and its S-enantiomer, esketamine, is separately FDA approved as Spravato for specific depressive disorders under a restricted administration program.

The addiction comparison also differs. Both PCP and ketamine can be misused and can lead to compulsive use, but chronic ketamine misuse has a particularly well-documented association with destructive urinary-tract disease, abdominal pain and cognitive problems. PCP has a stronger historical association with prolonged psychosis, severe agitation, hypertension, nystagmus and unpredictable toxic behavior.

PCP vs Ketamine at a Glance

Shared Dissociative Pharmacology, Different Clinical Drugs

Why PCP and ketamine are compared

Ketamine was developed after PCP as a dissociative anesthetic with a more manageable clinical profile. Both drugs interrupt NMDA-mediated glutamate signaling and can cause detachment from the body, altered perception, analgesia and changes in memory.

The comparison is useful because it shows how drugs in the same pharmacologic family can have very different medical roles. Shared receptor activity does not mean equivalent duration, safety, legal status or chronic complications.

Why ketamine replaced PCP in medicine

PCP’s anesthetic properties were clinically useful, but prolonged and disturbing emergence reactions limited human use. Ketamine was introduced as a related dissociative anesthetic with a shorter, more manageable course.

Today, FDA-approved ketamine products are used as general anesthetics in controlled medical settings. This includes known concentration, sterile formulation, clinical screening and physiologic monitoring. None of those safeguards apply to illicit PCP.

Medical Status and Regulatory Differences

Ketamine’s current FDA-approved role

FDA-approved ketamine is indicated as a general anesthetic. FDA continues to state that ketamine itself is not approved for psychiatric disorders such as depression, even though off-label psychiatric use occurs in practice.

Esketamine is different. Spravato is an FDA-approved nasal esketamine product for specific depression indications and is administered through a restricted program because of risks including sedation, dissociation, respiratory depression and abuse or misuse.

Medical ketamine vs street ketamine

Medical ketamine is supplied in standardized pharmaceutical formulations and given under professional monitoring. A powder sold illicitly as ketamine has uncertain identity, purity and concentration.

This distinction matters whenever someone claims that recreational ketamine must be safe because “doctors use it.” Medical use describes a controlled context, not a general safety guarantee for unsupervised or unknown-source use.

Duration and Acute Intoxication

Which lasts longer?

PCP generally produces a longer and more variable clinical course. Current PCP toxicology guidance cites an estimated half-life around 21 hours and notes that symptoms can last many hours, occasionally longer in severe exposure.

Ketamine is shorter acting in typical medical use, which was one reason it became more practical as an anesthetic. Illicit repeated ketamine use can still produce prolonged impairment, especially when combined with alcohol or sedatives.

Psychosis and severe agitation

Both drugs can produce hallucinations, dissociation and psychosis-like experiences. PCP has a particularly strong historical association with severe paranoia, disorganized behavior and psychotic reactions that sometimes persist after acute intoxication.

Ketamine can also produce acute perceptual disturbance and, with repeated heavy misuse, persistent dissociative, depressive or delusional symptoms. The 2026 systematic review of ketamine misuse treatment describes cognitive, affective and psychotic disturbances among chronic complications.

Long-Term Harms: Where PCP and Ketamine Diverge Most

Ketamine bladder and uropathy

Frequent ketamine misuse is strongly associated with ketamine-induced cystitis and broader uropathy. Symptoms can include urinary frequency, urgency, severe bladder pain, painful urination and blood in the urine. Severe disease can reduce bladder capacity, affect the ureters and contribute to upper urinary-tract damage.

Recent addiction-medicine and urologic reviews emphasize cessation of ketamine as a central part of management. Continuing ketamine because it temporarily reduces pain can create a destructive cycle in which the drug contributing to bladder injury is also used to cope with the resulting symptoms.

PCP is not known for this characteristic chronic bladder syndrome, which is one of the clearest clinically useful differences between the two drugs.

Cognitive effects and dependence

Repeated use of both drugs has been associated with memory and cognitive problems. Ketamine research more consistently documents deficits in working and episodic memory among frequent users. PCP literature also describes persistent memory and thought difficulties, although much of the evidence is older.

There is no scientifically useful single ranking of which drug is “more addictive.” PCP abuse and dependence are well described, and ketamine can also produce tolerance, psychological dependence and repeated unsuccessful attempts to stop.

What the 2026 ketamine misuse review adds

A 2026 systematic review identified 73 studies of interventions for ketamine misuse and found that treatment evidence remains fragmented. Reported approaches included psychotherapy, supportive medical care and several off-label medications, but the authors concluded that robust evidence for standardized pharmacologic treatment is still lacking.

The review also highlights the need for integrated care because ketamine misuse can involve psychiatric symptoms, bladder disease and gastrointestinal complications at the same time.

Addiction, Withdrawal and Testing

Withdrawal

Neither drug is defined by the same classic life-threatening withdrawal syndrome as alcohol or benzodiazepines. Repeated users can still develop craving, mood changes and sleep disturbance after stopping.

Ketamine dependence is increasingly described in modern addiction literature, while PCP withdrawal evidence is older and less standardized. In both cases, the treatment need can be severe even without a stereotyped dangerous physical withdrawal.

Drug testing

PCP is included in many routine urine drug-screen panels. Ketamine generally requires more specific testing and is not automatically detected by a PCP immunoassay.

A negative PCP screen therefore does not rule out ketamine or another dissociative. Likewise, a PCP-positive screening result should be confirmed if the clinical situation is inconsistent.

Unknown street powders and misidentification

Illicit powders cannot be reliably distinguished by appearance. An unknown white or off-white powder may be ketamine, PCP, another dissociative or a completely different substance. Street names and packaging are not chemical confirmation.

For this reason, treatment of acute toxicity is guided by the clinical syndrome while laboratory analysis clarifies the substance when needed.

Overdose Risk and Treatment Differences

Emergency risk

Both drugs can cause severe intoxication, but PCP is more strongly associated with prolonged psychosis, severe hypertension, nystagmus, seizures and traumatic injury. Ketamine can cause profound dissociation, reduced consciousness, vomiting and injury, with the risk changing substantially when alcohol, opioids or sedatives are also present.

Naloxone does not reverse either dissociative, but it should still be given if an opioid co-exposure may be suppressing breathing.

Addiction-treatment differences

PCP use disorder has no FDA-approved medication. Treatment focuses on behavioral care, psychiatric stabilization and the person’s broader substance-use pattern.

Ketamine misuse also lacks a well-established approved addiction medication. Heavy ketamine users may additionally need urologic, gastrointestinal or pain care because of complications that are much more characteristic of chronic ketamine exposure.

Why This Comparison Matters for Someone Choosing Treatment

A person with repeated PCP psychosis may need an addiction program with strong psychiatric capability and experience managing persistent substance-induced psychotic symptoms. A heavy ketamine user with urinary pain, hematuria or reduced bladder capacity may need addiction treatment coordinated with urology. Those are not interchangeable treatment problems simply because both drugs are dissociatives.

The comparison also prevents two common errors: assuming illicit ketamine is safe because ketamine is used in hospitals, and assuming PCP is essentially an older version of the same modern therapeutic drug. Their shared NMDA pharmacology is real, but the medical context and chronic harm profiles are meaningfully different.

Frequently Asked Questions About PCP vs Ketamine

Are PCP and ketamine the same drug?

No. They are related NMDA-antagonist dissociatives but have different pharmacology, duration, legal status and medical roles.

Is ketamine FDA approved?

Yes, ketamine is FDA approved as a general anesthetic. Ketamine itself is not FDA approved for psychiatric disorders. Esketamine is separately approved for specific depression indications.

Which lasts longer, PCP or ketamine?

PCP generally has the longer and more variable clinical course.

Which drug causes bladder damage?

Chronic ketamine misuse is strongly associated with ketamine-induced cystitis and uropathy.

Can both drugs become addictive?

Yes. Both can be misused and can lead to compulsive or dependent use.

Sources

• NCBI Bookshelf: Phencyclidine Toxicity: PCP pharmacology and clinical toxicology.
• FDA, June 2026: FDA-approved ketamine is a Schedule III general anesthetic; ketamine itself is not FDA-approved for psychiatric disorders.
• FDA: Spravato (esketamine): approved esketamine nasal spray, restricted administration and dissociation / sedation safety information.
• Ketamine use: a review: chronic ketamine misuse, cognitive effects, dependence and ketamine-induced cystitis.
• Ketamine-induced cystitis: an in-depth review for addiction medicine: current clinical overview of ketamine-associated bladder injury.
• Treatment and management approaches for ketamine misuse: a systematic review, 2026: current evidence on ketamine misuse treatment and associated complications.